News

Nath Bio-Genes (India) announced that the 33th Annual General Meeting(AGM) of the company will be held on 24 September 2026.

Net profit of Nath Bio-Genes (India) rose 14.07% to Rs 32.26 crore in the quarter ended June 2026 as against Rs 28.28 crore during the previous quarter ended June 2025. Sales rose 15.76% to Rs 328.40 crore in the quarter ended June 2026 as against Rs 283.70 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales328.40283.70 16 OPM %10.7010.32 - PBDT32.7927.86 18 PBT31.7826.88 18 NP32.2628.28 14 Powered by Capital Market - Live News

Nath Bio-Genes (India) will hold a meeting of the Board of Directors of the Company on 29 July 2026.

Net loss of Nath Bio-Genes (India) reported to Rs 0.01 crore in the quarter ended March 2026 as against net profit of Rs 1.48 crore during the previous quarter ended March 2025. Sales declined 0.73% to Rs 51.59 crore in the quarter ended March 2026 as against Rs 51.97 crore during the previous quarter ended March 2025.For the full year,net profit rose 7.85% to Rs 41.63 crore in the year ended March 2026 as against Rs 38.60 crore during the previous year ended March 2025. Sales rose 21.98% to Rs 445.10 crore in the year ended March 2026 as against Rs 364.91 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales51.5951.97 -1 445.10364.91 22 OPM %8.680.81 -11.7813.64 - PBDT2.262.91 -22 44.2643.86 1 PBT1.231.57 -22 40.2940.04 1 NP-0.011.48 PL 41.6338.60 8 Powered by Capital Market - Live News

Nath Bio-Genes (India) announced that the Board of Directors of the Company at its meeting held on 4 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.